Literature DB >> 7529336

Gamma interferon-induced, nitric oxide-mediated inhibition of vaccinia virus replication.

N Harris1, R M Buller, G Karupiah.   

Abstract

Gamma interferon (IFN-gamma)-induced nitric oxide synthase (iNOS) and nitric oxide (NO) production in the murine macrophage-like RAW 264.7 cells were previously shown to inhibit the replication of the poxviruses vaccinia virus (VV) and ectromelia virus and herpes simplex virus type 1. In the current study, we performed biochemical analyses to determine the stage in the viral life cycle blocked by IFN-gamma-induced NO. Antibodies specific for temporally expressed viral proteins, a VV-specific DNA probe, and transmission electron microscopy were used to show that the cytokine-induced NO inhibited late protein synthesis, DNA replication, and virus particle formation but not expression of the early proteins analyzed. Essentially similar results were obtained with hydroxyurea and cytosine arabinoside, inhibitors of DNA replication. Enzymatically active iNOS was detected in the lysates of IFN-gamma-treated but not in untreated RAW 264.7 cells. The IFN-gamma-treated RAW 264.7 cells which express iNOS not only were resistant to productive infection but also efficiently blocked the replication of VV in infected bystander cells of epithelial origin. This inhibition was arginine dependent, correlated with nitric production in cultures, and was reversible by the NOS inhibitor N omega-monomethyl-L-arginine.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7529336      PMCID: PMC188659     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  37 in total

1.  Murine cytotoxic activated macrophages inhibit aconitase in tumor cells. Inhibition involves the iron-sulfur prosthetic group and is reversible.

Authors:  J C Drapier; J B Hibbs
Journal:  J Clin Invest       Date:  1986-09       Impact factor: 14.808

2.  Targeting of a multicomponent transcription apparatus into assembling vaccinia virus particles requires RAP94, an RNA polymerase-associated protein.

Authors:  Y Zhang; B Y Ahn; B Moss
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

3.  Resistance of vaccinia virus to interferon is related to an interference phenomenon between the virus and the interferon system.

Authors:  E Paez; M Esteban
Journal:  Virology       Date:  1984-04-15       Impact factor: 3.616

4.  Induction of nitrite/nitrate synthesis in murine macrophages by BCG infection, lymphokines, or interferon-gamma.

Authors:  D J Stuehr; M A Marletta
Journal:  J Immunol       Date:  1987-07-15       Impact factor: 5.422

5.  Preferential effect of gamma interferon on the synthesis of HLA antigens and their mRNAs in human cells.

Authors:  D Wallach; M Fellous; M Revel
Journal:  Nature       Date:  1982-10-28       Impact factor: 49.962

6.  Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production.

Authors:  A H Ding; C F Nathan; D J Stuehr
Journal:  J Immunol       Date:  1988-10-01       Impact factor: 5.422

7.  Mechanism of interferon action: human leukocyte and immune interferons regulate the expression of different genes and induce different antiviral states in human amnion U cells.

Authors:  C E Samuel; G S Knutson
Journal:  Virology       Date:  1983-10-30       Impact factor: 3.616

8.  Functional role of type I and type II interferons in antiviral defense.

Authors:  U Müller; U Steinhoff; L F Reis; S Hemmi; J Pavlovic; R M Zinkernagel; M Aguet
Journal:  Science       Date:  1994-06-24       Impact factor: 47.728

9.  Nitric oxide. A macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells.

Authors:  D J Stuehr; C F Nathan
Journal:  J Exp Med       Date:  1989-05-01       Impact factor: 14.307

10.  Sites of inhibition of mitochondrial electron transport in macrophage-injured neoplastic cells.

Authors:  D L Granger; A L Lehninger
Journal:  J Cell Biol       Date:  1982-11       Impact factor: 10.539

View more
  69 in total

1.  Evaluation of non-reciprocal heterologous immunity between unrelated viruses.

Authors:  Jenny W Che; Liisa K Selin; Raymond M Welsh
Journal:  Virology       Date:  2015-03-31       Impact factor: 3.616

2.  Nitric oxide inhibition of coxsackievirus replication in vitro.

Authors:  C Zaragoza; C J Ocampo; M Saura; A McMillan; C J Lowenstein
Journal:  J Clin Invest       Date:  1997-10-01       Impact factor: 14.808

Review 3.  Initiation of primary anti-vaccinia virus immunity in vivo.

Authors:  Matthew A Fischer; Christopher C Norbury
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

4.  Exposure of rhesus monkeys to cowpox virus Brighton Red by large-particle aerosol droplets results in an upper respiratory tract disease.

Authors:  Reed F Johnson; Dima A Hammoud; Donna L Perry; Jeffrey Solomon; Ian N Moore; Matthew G Lackemeyer; Jordan K Bohannon; Philip J Sayre; Mahnaz Minai; Amy B Papaneri; Katie R Hagen; Krisztina B Janosko; Catherine Jett; Kurt Cooper; Joseph E Blaney; Peter B Jahrling
Journal:  J Gen Virol       Date:  2016-05-09       Impact factor: 3.891

5.  The cytotoxic T-lymphocyte response to Sendai virus is unimpaired in the absence of gamma interferon.

Authors:  X Y Mo; R A Tripp; M Y Sangster; P C Doherty
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

6.  Disassociation between the in vitro and in vivo effects of nitric oxide on a neurotropic murine coronavirus.

Authors:  T E Lane; A D Paoletti; M J Buchmeier
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

7.  Vesicular stomatitis virus infection of the central nervous system activates both innate and acquired immunity.

Authors:  Z Bi; M Barna; T Komatsu; C S Reiss
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

8.  Activity of nitric oxide-generating compounds against encephalomyocarditis virus.

Authors:  E Guillemard; M Geniteau-Legendre; R Kergot; G Lemaire; J F Petit; C Labarre; A M Quero
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

9.  Interleukin-18 protects mice against acute herpes simplex virus type 1 infection.

Authors:  N Fujioka; R Akazawa; K Ohashi; M Fujii; M Ikeda; M Kurimoto
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

10.  Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses.

Authors:  Igor M Belyakov; Patricia Earl; Amiran Dzutsev; Vladimir A Kuznetsov; Michael Lemon; Linda S Wyatt; James T Snyder; Jeffrey D Ahlers; Genoveffa Franchini; Bernard Moss; Jay A Berzofsky
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-17       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.